Barclays’s Aimmune Therapeutics AIMT Stock Holding History

Barclays’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-100	Closed	-$1K	–	6515
2020 Q1	$1K	Buy	+100	New	+$2.56K	﹤0.01%	6095
2018 Q1	–	Sell	-95,000	Closed	-$3.59M	–	7484
2017 Q4	$3.59M	Buy	+95,000	New	+$3.07M	﹤0.01%	1914

Barclays's AIMT Position: Q4 2020 in Review

Barclays sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 133,703 shares — an estimated $4.61M sold.

Barclays first reported a position in AIMT in Q3 2016 and held it in 17 quarters. The position peaked at $5.91M in Q4 2017. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Barclays reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Barclays sold 133,703 Aimmune Therapeutics shares in Q4 2020, an estimated $4.61M.
Barclays first reported a position in Aimmune Therapeutics in Q3 2016 and held it in 17 quarters.
Barclays's Aimmune Therapeutics position peaked at $5.91M in Q4 2017.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Barclays's 13F filing for Q4 2020, filed 11 Feb 2021.